.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Healthtrust
Moodys
Queensland Health
McKinsey
Daiichi Sankyo
Merck
Fish and Richardson
US Department of Justice
UBS

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021903

« Back to Dashboard
NDA 021903 describes NEOPROFEN, which is a drug marketed by Recordati Rare and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NEOPROFEN profile page.

The generic ingredient in NEOPROFEN is ibuprofen lysine. There are sixty-four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ibuprofen lysine profile page.

Summary for 021903

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:3
Formulation / Manufacturing:see details

Pharmacology for NDA: 021903

Suppliers and Packaging for NDA: 021903

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEOPROFEN
ibuprofen lysine
INJECTABLE;INTRAVENOUS 021903 NDA RECORDATI RARE DISEASES, INC. 55292-122 55292-122-52 3 VIAL in 1 CARTON (55292-122-52) > 2 mL in 1 VIAL
NEOPROFEN
ibuprofen lysine
INJECTABLE;INTRAVENOUS 021903 NDA AUTHORIZED GENERIC Prasco Laboratories 66993-490 66993-490-36 3 VIAL in 1 CARTON (66993-490-36) > 2 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrengthEQ 20MG BASE/2ML (EQ 10MG BASE/ML)
Approval Date:Apr 13, 2006TE:APRLD:Yes
Patent:► SubscribePatent Expiration:Nov 14, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
Patent:► SubscribePatent Expiration:Nov 14, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PATENT DUCTUS ARTERIOSUS
Patent:► SubscribePatent Expiration:Mar 20, 2021Product Flag?YSubstance Flag?YDelist Request?Y
Patented Use:CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Julphar
Citi
Medtronic
McKesson
Healthtrust
Fish and Richardson
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot